# OnCo record aumolertinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/aumolertinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "aumolertinib" ;
  schema:name "Aumolertinib"@en ;
  schema:alternateName "Aumseqa"@en, "Almonertinib"@en, "Ameile" ;
  schema:description "Aumolertinib is Hansoh's third-generation lung cancer pill, the first China-developed drug of its class, approved for first-line EGFR-mutant lung cancer on the AENEAS trial."@en ;
  schema:url <https://onco.cc/drugs/aumolertinib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Almonertinib> ;
  schema:citation <https://www.hspharm.com/>, <https://doi.org/10.1200/JCO.21.02641>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule third-generation EGFR TKI" ;
  onco:approval "China 2020: EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy", "China 2021: First-line EGFR exon 19 deletion or L858R NSCLC (AENEAS)", "EU 2026: Aumseqa: first-line advanced NSCLC with EGFR exon 19 deletion or L858R; advanced EGFR T790M-positive NSCLC" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/hansoh-pharma/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/egfr-mutation-subtypes/> ;
  onco:trials <https://onco.cc/trials/aeneas/>, <https://onco.cc/trials/nct07183189/>, <https://onco.cc/trials/nct04687241/>, <https://onco.cc/trials/nct04951635/>, <https://onco.cc/trials/nct04923906/>, <https://onco.cc/trials/nct06474455/> .